Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance
- PMID: 19076434
- PMCID: PMC2745097
- DOI: 10.1196/annals.1427.023
Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance
Abstract
Parkinson's disease (PD) is a common adult-onset neurodegenerative disorder. Typically PD is a sporadic neurological disorder, and over time affected patients see their disability growing and their quality of life declining. Oxidative stress has been hypothesized to be linked to both the initiation and the progression of PD. Preclinical findings from both in vitro and in vivo experimental models of PD suggest that the neurodegenerative process starts with otherwise healthy neurons being hit by some etiological factors, which sets into motion a cascade of deleterious events. In these models initial molecular alterations in degenerating dopaminergic neurons include increased formation of reactive oxygen species, presumably originating from both inside and outside the mitochondria. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD, time-course experiments suggest that oxidative stress is an early event that may directly kill some of the dopaminergic neurons. In this model it seems that oxidative stress may play a greater role in the demise of dopaminergic neurons indirectly by activating intracellular, cell death-related, molecular pathways. As the neurodegenerative process evolves in the MPTP mouse model, indices of neuroinflammation develop, such as microglial activation. The latter increases the level of oxidative stress to which the neighboring compromised neurons are subjected to, thereby promoting their demise. However, these experimental studies have also shown that oxidative stress is not the sole deleterious factor implicated in the death of dopaminergic neurons. Should a similar multifactorial cascade underlie dopaminergic neuron degeneration in PD, then the optimal therapy for this disease may have to rely on a cocktail of agents, each targeting a different critical component of this hypothesized pathogenic cascade. If correct, this may be a reason why neuroprotective trials using a single agent, such as an antioxidant, have thus far generated disappointing results.
Similar articles
-
Human Amniotic Epithelial Cells Alleviate a Mouse Model of Parkinson's Disease Mainly by Neuroprotective, Anti-Oxidative and Anti-Inflammatory Factors.J Neuroimmune Pharmacol. 2021 Sep;16(3):620-633. doi: 10.1007/s11481-020-09969-w. Epub 2020 Nov 9. J Neuroimmune Pharmacol. 2021. PMID: 33164162
-
Sofalcone attenuates neurodegeneration in MPTP-induced mouse model of Parkinson's disease by inhibiting oxidative stress and neuroinflammation.Mol Biol Rep. 2024 Aug 14;51(1):908. doi: 10.1007/s11033-024-09852-4. Mol Biol Rep. 2024. PMID: 39141244
-
Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.Neuroscience. 2014 Jul 11;272:167-79. doi: 10.1016/j.neuroscience.2014.04.039. Epub 2014 Apr 30. Neuroscience. 2014. PMID: 24792712
-
The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.Curr Pharm Des. 2011;17(5):489-507. doi: 10.2174/138161211795164095. Curr Pharm Des. 2011. PMID: 21375482 Review.
-
Neuroprotective strategies in Parkinson's disease : an update on progress.CNS Drugs. 2003;17(10):729-62. doi: 10.2165/00023210-200317100-00004. CNS Drugs. 2003. PMID: 12873156 Review.
Cited by
-
Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson's model: a promising candidate for the treatment of Parkinson's disease.Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):265-75. doi: 10.1007/s00210-011-0710-2. Epub 2011 Nov 27. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22119889
-
Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy for these devastating disorders.Mech Ageing Dev. 2020 Sep;190:111297. doi: 10.1016/j.mad.2020.111297. Epub 2020 Jun 28. Mech Ageing Dev. 2020. PMID: 32610099 Free PMC article. Review.
-
Gene therapy: a viable therapeutic strategy for Parkinson's disease?J Neurol. 2011 Feb;258(2):179-88. doi: 10.1007/s00415-010-5796-9. Epub 2010 Oct 21. J Neurol. 2011. PMID: 20963433 Review.
-
The Role of Mitochondrial Damage-Associated Molecular Patterns in Chronic Neuroinflammation.Mediators Inflamm. 2019 Apr 1;2019:4050796. doi: 10.1155/2019/4050796. eCollection 2019. Mediators Inflamm. 2019. PMID: 31065234 Free PMC article. Review.
-
Strategy to Suppress Oxidative Damage-Induced Neurotoxicity in PC12 Cells by Curcumin: the Role of ROS-Mediated DNA Damage and the MAPK and AKT Pathways.Mol Neurobiol. 2016 Jan;53(1):369-378. doi: 10.1007/s12035-014-9021-1. Epub 2014 Nov 30. Mol Neurobiol. 2016. PMID: 25432891
References
-
- DAUER W, PRZEDBORSKI S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889–909. - PubMed
-
- FAHN S, PRZEDBORSKI S. Parkinsonism. In: Rowland LP, editor. Merritt's Neurology. Lippincott Williams & Wilkins; New York: 2005. pp. 828–846.
-
- POLYMEROPOULOS MH, LAVEDAN C, LEROY E, IDE SE, DEHEJIA A, DUTRA A, PIKE B, ROOT H, RUBENSTEIN J, BOYER R, STENROOS ES, CHANDRASEKHARAPPA S, ATHANASSIADOU A, PAPAPETROPOULOS T, JOHNSON WG, LAZZARINI AM, DUVOISIN RC, DI IORIO G, GOLBE LI, NUSSBAUM RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045–2047. - PubMed
-
- KITADA T, ASAKAWA S, HATTORI N, MATSUMINE H, YAMAMURA Y, MINOSHIMA S, YOKOCHI M, MIZUNO Y, SHIMIZU N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–608. - PubMed
-
- BONIFATI V, RIZZU P, VAN BAREN MJ, SCHAAP O, BREEDVELD GJ, KRIEGER E, DEKKER MC, SQUITIERI F, IBANEZ P, JOOSSE M, VAN DONGEN JW, VANACORE N, VAN SWIETEN JC, BRICE A, MECO G, VAN DUIJN CM, OOSTRA BA, HEUTINK P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256–259. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials